← Leaderboards
Joseph Christopher Mudd
Tulane University Of Louisiana
$5,625,443
Attributed
$7,212,279
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2020–25$2.5M$1.9M$1.3M$625K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,212,279 · 6
By mechanism
R01$4,959,113 · 2
R21$1,077,836 · 2
R56$908,973 · 1
K22$266,357 · 1
Top collaborators
- Joshua Tisdell Schiffer3 shared
- Adam Mitchell Spivak3 shared
Most similar at Tulane University Of Louisiana
Same institution · by research overlap
- Ivona Pandrea$33,088,190
- Mahesh Mohan$12,801,428
- Angela M Amedee$2,356,313
- Elizabeth Schmidt Didier$8,050,961
- Vicki L Traina-Dorge$5,386,412
Others in their field
Other Emerging Leaders on “In Vivo”
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,216,744
- Leonard Freedmand · Leidos Biomedical Research, Inc.$66,248,714
- John Damon Chodera · Sloan-Kettering Inst Can Research$43,427,103
- Tony Moody · Duke University$34,777,314
- Alan D. Palkowitz · Indiana University Indianapolis$18,925,366
Research focus
In VivoHiv-1Antiretroviral TherapyInfectionCd4 Positive T LymphocytesViralMacaca MulattaAnimalsPersonsProvirusesVirusCellsTissuesInterestComorbiditySamplingT-LymphocyteAntigensProliferatingIntegration SiteFda ApprovedAnimal ModelMolecularDeuterium
Grant awards (13)
Early intervention with anti-proliferative therapy close to ART initiation to limit long-term SIV persistence$846,498
R01 · FY2025 · AI
Role of RhCMV in shaping the SIV proviral landscape$779,297
R01 · FY2025 · AI · contact PI
Role of RhCMV in shaping the SIV proviral landscape$832,867
R01 · FY2024 · AI · contact PI
Early intervention with anti-proliferative therapy close to ART initiation to limit long-term SIV persistence$624,783
R01 · FY2024 · AI
The intersection of diet, cell metabolic state, and SIV reservoir transcription$212,215
R21 · FY2024 · AI · contact PI
Role of RhCMV in shaping the SIV proviral landscape$1,024,940
R01 · FY2023 · AI · contact PI
Early intervention with anti-proliferative therapy close to ART initiation to limit long-term SIV persistence$908,973
R56 · FY2023 · AI
The intersection of diet, cell metabolic state, and SIV reservoir transcription$254,286
R21 · FY2023 · AI · contact PI
Role of RhCMV in shaping the SIV proviral landscape$850,728
R01 · FY2022 · AI · contact PI
Mechanisms and Therapeutic Targeting of CD4 Down regulation in African Green Monkeys$321,800
R21 · FY2022 · OD · contact PI
Mechanisms and Therapeutic Targeting of CD4 Down regulation in African Green Monkeys$289,535
R21 · FY2021 · OD · contact PI
Innate Lymphoid Cell Loss in HIV-1 and SIV Infection$108,000
K22 · FY2021 · AI · contact PI
Innate Lymphoid Cell Loss in HIV-1 and SIV Infection$158,357
K22 · FY2020 · AI · contact PI